A 12-Week, Randomised, Double-Blind, Placebo-Controlled Study to Assess the Anti-Inflammatory Activity, Efficacy and Safety of GW856553 in Subjects With Chronic Obstructive Pulmonary Disease (COPD).

Trial Profile

A 12-Week, Randomised, Double-Blind, Placebo-Controlled Study to Assess the Anti-Inflammatory Activity, Efficacy and Safety of GW856553 in Subjects With Chronic Obstructive Pulmonary Disease (COPD).

Completed
Phase of Trial: Phase II

Latest Information Update: 20 Aug 2017

At a glance

  • Drugs Losmapimod (Primary) ; Salmeterol/fluticasone propionate
  • Indications Chronic obstructive pulmonary disease
  • Focus Therapeutic Use
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 19 Apr 2012 Planned number of patients changed from 300 to 740 as reported by European Clinical Trials Database.
    • 19 Feb 2010 Actual patient number (306) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top